List of Excipients in Branded Drug TROSPIUM CHLORIDE

Generic Drugs Containing TROSPIUM CHLORIDE

Company	Ingredient	NDC	Excipient
Padagis US LLC	trospium chloride	0574-0118	FD&C YELLOW NO. 6
Padagis US LLC	trospium chloride	0574-0118	FERROSOFERRIC OXIDE
Padagis US LLC	trospium chloride	0574-0118	GELATIN
Padagis US LLC	trospium chloride	0574-0118	MAGNESIUM ALUMINUM SILICATE
Padagis US LLC	trospium chloride	0574-0118	MAGNESIUM STEARATE
Padagis US LLC	trospium chloride	0574-0118	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

What are the Most Frequently-Used Excipients in TROSPIUM CHLORIDE?

# Of NDCs	Excipient
5	AMMONIA
6	BUTYL ALCOHOL
8	CALCIUM CARBONATE
2	CARBOXYMETHYLCELLULOSE
19	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE K25-31

Trospium Chloride Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Trospium chloride is a mature oral antimuscarinic used for overactive bladder and related urinary urgency, frequency, and urge-incontinence symptoms. Its commercial opportunity is no longer based on compound exclusivity. Value is concentrated in formulation performance, food-effect control, adherence, age-friendly dosage forms, manufacturing efficiency, and differentiated modified-release products.

The most attractive excipient strategy is a controlled-release oral platform that reduces dosing burden without increasing peak-related adverse effects. Immediate-release generics face limited differentiation because trospium chloride tablets are already established, inexpensive, and substitutable.

What is the FDA regulatory status of trospium chloride?

Trospium chloride is an FDA-approved small-molecule prescription drug. The reference products are Sanctura immediate-release tablets and Sanctura XR extended-release capsules, historically associated with Allergan and its predecessor entities.

Attribute	Trospium chloride
Therapeutic class	Antimuscarinic urinary antispasmodic
Primary indication	Overactive bladder with urgency, frequency, and urge urinary incontinence
Original reference product	Sanctura
Extended-release product	Sanctura XR
Immediate-release strength	20 mg tablet
Extended-release strength	60 mg capsule
Regulatory pathway for generics	ANDA, subject to reference-product requirements
Molecular type	Small molecule
Biosimilar exposure	None
Main formulation issue	Low and variable oral exposure, food effect, and adherence burden

Trospium chloride is a quaternary ammonium antimuscarinic. Its permanent positive charge limits passive membrane diffusion and reduces central nervous system penetration relative to more lipophilic antimuscarinics. The same property contributes to low oral bioavailability and makes oral formulation design important.[1]

The immediate-release product is generally administered on an empty stomach because food can reduce systemic exposure. The labeling recommends administration at least one hour before a meal or on an empty stomach at bedtime.[1] That restriction creates a clear formulation-development opportunity.

What excipients are used in trospium chloride products?

Trospium chloride products use conventional oral solid-dose excipients. The precise composition varies by manufacturer and dosage form, and generic formulations are not required to use the same inactive ingredients as the reference product if they meet applicable regulatory and bioequivalence requirements.

Immediate-release tablets

Typical excipient functions include:

Excipient category	Examples used in oral tablets	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose	Tablet mass and manufacturability
Binder	Povidone	Granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup
Lubricant	Magnesium stearate, stearic acid	Ejection and tooling control
Glidant	Colloidal silicon dioxide	Powder flow
Coating system	Hypromellose, pigments, plasticizer	Identification, swallowability, stability

A generic immediate-release product can compete on low manufacturing cost, compact tablets, reduced excipient count, or avoidance of specific excipients such as lactose, gelatin, colorants, or artificial dyes.

Extended-release capsules

Extended-release trospium products require a release-controlling system rather than simple tablet disintegration. Candidate technologies include:

• Hydrophilic matrix tablets or pellets using hypromellose.
• Insoluble polymer coatings using ethylcellulose or acrylic polymers.
• Multiparticulate beads filled into hard capsules.
• Ion-exchange resin complexes.
• Osmotic or membrane-controlled systems.
• Combination immediate-release and extended-release bead populations.

The formulation objective is to sustain delivery while limiting the initial concentration peak. Multiparticulate systems can offer more consistent gastrointestinal distribution than a single monolithic matrix and may reduce sensitivity to gastric residence time.

Which excipient strategy best addresses trospium chloride’s food effect?

The strongest commercial strategy is a food-robust modified-release formulation.

Trospium chloride’s food restriction creates an adherence problem because patients must coordinate dosing with meals. A formulation that produces comparable exposure under fed and fasted conditions could support a differentiated product, although the FDA would require evidence that the new formulation is clinically and pharmacokinetically appropriate.

Potential approaches include:

1. Multiparticulate delivery. Coated pellets can distribute drug throughout the gastrointestinal tract and reduce dependence on one gastric environment.

2. Controlled wetting and dissolution. Surfactants or wetting agents may improve reproducibility, but excessive solubilization could increase peak exposure or produce food-dependent precipitation.

3. Polymer-controlled release. Hydrophilic or insoluble polymers can reduce the rate at which drug becomes available in the stomach and intestine.

4. Lipid or self-emulsifying systems. These may improve dissolution but require careful control because lipid digestion and meal composition can create new variability.

5. pH-modifying excipients. Buffering agents may improve dissolution consistency, but the formulation must account for the drug’s ionic character and gastrointestinal pH changes.

6. Dosage-form placement. A capsule containing dispersed pellets may provide more consistent release than a single tablet, particularly in patients with variable gastric emptying.

Food-effect claims are commercially valuable only if supported by a meaningful reduction in dosing restrictions. A formulation that remains label-restricted despite complex excipient technology would have limited payer and prescriber differentiation.

What formulation patents could protect a trospium chloride product?

The original trospium chloride compound and conventional immediate-release tablet technology are mature. New patent value would most likely arise from formulation-specific claims.

Potential claim categories include:

Claim category	Potential protection
Composition	Defined polymer, plasticizer, pore former, lubricant, or multiparticulate composition
Release profile	Dissolution limits at specified pH values and time points
Food-effect control	Fed/fasted exposure ratio within a defined range
Particle engineering	Pellet size, coating thickness, drug loading, or porosity
Manufacturing process	Fluid-bed coating, granulation, curing, or capsule-filling parameters
Dosage regimen	Once-daily administration or administration independent of meals
Stability	Resistance to degradation, moisture uptake, or capsule-shell interaction
Combination product	Trospium with another urinary or pelvic-floor therapy

Patent strength depends on whether the claims cover a clinically meaningful formulation result or only a narrow excipient combination. Broad claims directed to a routine polymer matrix may face obviousness challenges. Stronger protection would link the composition to a difficult-to-predict technical effect, such as a defined food-effect profile, reduced pharmacokinetic variability, or stable release across physiologically relevant pH conditions.

Manufacturing-process claims and know-how can supplement composition patents. They are particularly relevant where coating uniformity, pellet curing, or drug loading determines the release profile.

When does trospium chloride lose exclusivity?

Trospium chloride has no biosimilar pathway because it is a small molecule. The principal competitive threat is generic substitution through ANDA approvals.

The commercial exclusivity landscape is divided into three layers:

Layer	Current strategic relevance
Compound exclusivity	Mature and generally no longer the primary barrier
Immediate-release product exclusivity	Low, with generic substitution established
Extended-release formulation protection	Depends on listed patents, regulatory exclusivity, and the scope of formulation claims

Sanctura and Sanctura XR are listed reference products in FDA drug databases, but Orange Book patent status must be reviewed against the current edition because listings, certifications, and litigation positions can change.[2] A definitive launch analysis requires a current Orange Book review and a docket-by-docket assessment of any ANDA litigation.

What is the Orange Book status of trospium chloride?

The FDA Orange Book identifies reference-listed drugs, approved dosage forms, therapeutic equivalence evaluations, and patent or exclusivity information.[2] Trospium chloride immediate-release tablets and extended-release capsules should be evaluated separately because an ANDA applicant must match the relevant reference product’s dosage form, strength, route, and release characteristics.

For commercial diligence, the key Orange Book questions are:

• Are any patents currently listed against the relevant Sanctura or Sanctura XR reference product?
• Are those patents formulation, method-of-use, or manufacturing patents?
• Has an ANDA applicant submitted a Paragraph IV certification?
• Has the reference-product sponsor filed a 45-day patent-infringement action?
• Is a 30-month stay applicable?
• Is the proposed product eligible for a section viii carve-out rather than a Paragraph IV challenge?

A Paragraph IV challenge would be most relevant for a protected extended-release product. Immediate-release products with established generic competition have less attractive litigation economics unless a new patent listing creates a meaningful barrier.

Which commercial opportunities exist for trospium chloride excipient innovation?

Once-daily modified release

Once-daily dosing is the clearest product opportunity. A successful product could compete against twice-daily immediate-release tablets by improving adherence and simplifying prescribing.

The product would need to demonstrate:

• Comparable or clinically acceptable exposure.
• Controlled peak concentrations.
• Reliable release across pH conditions.
• Acceptable fed and fasted performance.
• No clinically meaningful accumulation.
• Stable performance in older adults and patients with renal impairment.

Food-independent dosing

A food-independent label could be more valuable than a modest reduction in tablet size. Patients with overactive bladder are often older and may take multiple medications. Removing meal timing restrictions reduces regimen complexity.

Lower-cost extended-release supply

The existing extended-release capsule concept can be targeted through generic or private-label supply. Opportunities include lower-cost coated-pellet manufacturing, simplified capsule filling, and regional contract-manufacturing arrangements.

Excipient-exclusion products

Potential niche products include formulations that avoid:

• Lactose for patients with intolerance concerns.
• Gelatin for dietary or religious requirements.
• Certain colorants.
• Titanium dioxide where market-specific restrictions apply.
• High tablet lubricant levels that can affect dissolution.
• Preservatives and unnecessary coating additives.

Excipient exclusion alone is unlikely to support a premium unless it is paired with a recognized patient, payer, or institutional procurement requirement.

Age-friendly dosage forms

Trospium chloride is used heavily in older populations, creating demand for:

• Smaller tablets or capsules.
• Improved swallowability.
• Sprinkle-capable multiparticulates.
• Unit-dose packaging.
• Blister packaging with adherence labeling.
• Low-volume oral suspensions for patients unable to swallow solid dosage forms.

A liquid or sprinkle product would face stability, taste, dosing accuracy, and administration-device requirements. The quaternary ammonium structure may also create taste challenges, making taste masking and packaging central to product design.

How does trospium chloride compare with competing overactive-bladder drugs?

Product class	Formulation advantage	Trospium chloride implication
Oxybutynin immediate release	Low-cost, established generic	Strong price competition
Oxybutynin transdermal	Avoids some oral exposure issues	Trospium has a weaker transdermal rationale because of its charged molecule
Tolterodine extended release	Once-daily oral dosing	Direct formulation benchmark
Solifenacin	Once-daily dosing and long half-life	Competes on convenience and persistence
Fesoterodine	Extended-release prodrug approach	Competes on controlled exposure
Mirabegron	Non-antimuscarinic mechanism	Competes where anticholinergic burden is a concern

Trospium’s principal clinical differentiation is limited central nervous system penetration relative to more lipophilic antimuscarinics. Its commercial weakness is dosing inconvenience and generic price pressure. An excipient-led product must exploit convenience without undermining its pharmacokinetic profile.

What generic entry risks exist for trospium chloride?

Immediate-release generic entry risk is high because the dosage form is conventional and the product has long been marketed. A new entrant would compete primarily through manufacturing cost, supply reliability, wholesaler access, and formulary contracting.

Extended-release generic entry is more technically difficult. Risks include:

• Failure to match the reference dissolution profile.
• Food-effect differences.
• Dose-dumping concerns.
• Capsule or pellet stability problems.
• Variability in coating thickness.
• Bioequivalence failure under fed conditions.
• Difficulty reproducing the reference product’s in vitro-in vivo relationship.

For a new branded formulation, the key risk is that a generic applicant may design around narrow excipient claims while matching the required pharmacokinetic and dissolution specifications.

What licensing and partnership opportunities exist?

Licensing value is most credible in three areas:

1. Controlled-release platforms. A developer with a validated pellet, matrix, or coating platform could license a trospium formulation to a generic or specialty-pharma company.

2. Regional commercialization. Trospium products can support in-licensing in markets where overactive-bladder treatment remains underpenetrated and local generic supply is limited.

3. Combination and adherence products. Partnerships may pair trospium with packaging, digital adherence support, or complementary urinary-tract therapies.

A deal based only on conventional immediate-release tablets would likely have limited strategic value. A partner would expect a differentiated formulation, regulatory filing, manufacturing advantage, or geographic rights.

What is the overall patent strength of a trospium chloride formulation program?

The underlying trospium chloride estate is commercially weak as a compound-centered opportunity because the active ingredient is mature and generic competition exists. A new formulation estate can be moderate to strong if it establishes several independent barriers:

• Composition claims covering the release system.
• Dissolution claims that are difficult to design around.
• Food-effect claims supported by clinical pharmacology.
• Process claims tied to manufacturing reproducibility.
• Method-of-use claims linked to an approved label.
• Trade secrets covering coating and curing conditions.

The strongest strategy is a layered estate around a once-daily, food-robust multiparticulate product. A single narrow excipient claim would provide limited protection.

Key Takeaways

• Trospium chloride is a mature small-molecule antimuscarinic with established immediate-release generic competition.
• The highest-value excipient opportunity is a once-daily, food-robust extended-release formulation.
• Multiparticulate coated pellets offer a credible platform for controlling release and reducing gastrointestinal variability.
• Excipient substitution alone is unlikely to justify a premium unless it solves a clear patient or procurement problem.
• The drug has no biosimilar risk; competition comes from ANDA applicants and reformulated generic products.
• Patent value should focus on release profiles, food-effect control, manufacturing processes, and dosage-form performance.
• Immediate-release products are primarily cost and supply-chain opportunities. Extended-release products offer greater technical and IP differentiation.
• Any current Paragraph IV, Orange Book, or litigation conclusion requires review of the latest FDA listings and court dockets.

FAQs

Can trospium chloride be formulated as an orally disintegrating tablet?

Yes, but the approach would need to manage bitterness, tablet friability, moisture sensitivity, and rapid exposure. An orally disintegrating tablet would improve administration but would not inherently solve trospium chloride’s food effect.

Is a transdermal trospium chloride product commercially attractive?

The permanent positive charge of trospium chloride limits passive skin penetration. A transdermal product would likely require a specialized enhancement system or device, creating a higher development burden than an oral modified-release product.

Can lactose-free trospium chloride support a premium product?

Usually not by itself. A lactose-free formulation could support institutional, regional, or patient-specific positioning, but premium pricing would require added convenience, superior stability, or a meaningful tolerability advantage.

Would a trospium chloride liquid require a new FDA application?

A materially different dosage form, such as an oral solution or suspension, may require a separate regulatory strategy rather than a conventional tablet ANDA. The pathway would depend on the reference product, formulation equivalence, labeling, and the extent of clinical or pharmaceutical differences.

What is the most defensible trospium chloride formulation patent strategy?

A layered strategy is strongest: multiparticulate composition claims, defined dissolution and food-effect claims, manufacturing-process claims, and approved-label method claims. The technical effect must be demonstrated with comparative pharmacokinetic and dissolution data.

References

1. U.S. Food and Drug Administration. (2023). Sanctura (trospium chloride) tablets prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Sanctura XR (trospium chloride extended-release capsules) prescribing information. FDA/DailyMed.

4. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

5. Staskin, D. R., MacDiarmid, S., & others. (2007). Trospium chloride extended-release capsules for overactive bladder. International Journal of Clinical Practice, 61(7), 1084-1090.